Prior Authorization in Fertility Billing: Getting It Right the First Time

Prior authorization in fertility billing is uniquely high-stakes. Unlike a single inpatient procedure where one authorization covers the admission, an IVF cycle may require separate authorizations for monitoring, egg retrieval, lab procedures, genetic testing, and embryo transfer — each with its own approval window, expiration date, and code-specific requirements. Missing any one authorization does not just delay payment — it can void the claim entirely, with no effective appeal path.

The Four Authorization Categories to Manage

• Stimulation monitoring authorization — covers E&M visits (99213) and ultrasound (76830) during the stimulation phase. Often separate from the cycle procedure authorization at major medical payers.
• Egg retrieval authorization — covers CPT 58970. Some payers include this in the cycle authorization; others require a separate request submitted after stimulation has begun.
• Lab procedure authorization — covers the 89xxx series (fertilization, embryo culture, ICSI, cryopreservation). Frequently missed because the embryology lab files separately, but authorization responsibility may rest with the clinic.
• Embryo transfer authorization — covers 58974 for fresh transfer or 58976 for FET. Fresh transfer authorizations have a narrow window tied to the retrieval date — a cancelled or delayed transfer may require a new auth.

What to Include in the Authorization Request

Authorization requests for IVF should include the diagnosis codes that establish medical necessity, the complete list of CPT codes being requested (not just the primary procedure), the treating provider's NPI, the anticipated date range, and a clinical summary as required by the payer. Submitting an incomplete request — omitting any CPT code, or using a diagnosis that differs from the clinical record — creates a mismatch when the claim arrives.

How Different Payer Categories Handle Fertility Prior Authorization

A single authorization workflow will not survive contact with the full payer mix a fertility practice sees in a year. The rules differ materially by product type — the same patient carrying the same diagnosis can require an authorization at one plan, no authorization at all at another, and a clinical-review escalation at a third. Building a workflow that treats every payer identically is the fastest way to accumulate CO-197 auth-mismatch denials.

• Mandate-state fully-insured commercial plans (BCBS, Aetna, Cigna, UHC state products in the 24 mandate states): authorization is routinely required on 58970, 58974, 58976, 89250-series lab codes, and PGT analysis codes. Statutory coverage means the auth is a documentation exercise rather than a coverage decision — but omitting the auth still voids the claim under CO-197.
• Non-mandate-state fully-insured commercial plans: authorization may be required for medical management of the underlying diagnosis (N97.x, E28.2) while IVF, ICSI, PGT, and FET remain benefit-excluded. Do not request auth for a benefit-excluded service — the denial arrives as CO-96 rather than approval, and the patient owes the full contracted rate.
• Self-funded ERISA plans: authorization requirements depend on the employer's plan document, not the payer's general policy. The same TPA (Aetna, Cigna, UHC as administrator) will apply different auth rules across two employers on the same benefit day because the underlying plan documents differ. Always verify against the specific member's plan, not the payer's general medical policy.
• Fertility benefit managers (Progyny, WINFertility, Carrot, Maven Clinic): authorization runs through the FBM portal, not the medical carrier. The FBM issues a case number or cycle tier authorization that governs which services are approved and at what quantity. The medical carrier's auth portal will typically return "no auth required" for the same CPT because the FBM has assumed that responsibility — do not read that response as a general auth waiver.
• Medicaid: authorization rules vary by state Medicaid program and by managed-care organization (MCO) within each state. Most state Medicaid programs authorize diagnostic services and medical management under N97.x / E28.2 but exclude the IVF cycle itself. A handful (NY, DC, ME managed-care variants) authorize select services with specific medical-necessity documentation.
• TRICARE: authorization for infertility diagnostic and medical management is generally available; ART authorization is restricted to service members with a service-connected serious or severe injury or illness per the 2016 NDAA policy. The auth pathway runs through the TRICARE regional contractor, not the local network provider portal.
• Federal Employees Health Benefits (FEHB): the BCBS Federal Employee Program (FEP), GEHA, and Kaiser FEHB each apply their own auth rules, and those rules changed materially in the 2024 and 2025 plan years as OPM negotiated expanded ART benefits. Verify each plan-year cycle rather than relying on prior-year documentation.

Documentation That Supports a First-Pass Auth Approval

The single largest cause of avoidable authorization denials is a clinical submission that is thin on the elements the medical reviewer needs to affirm medical necessity. Payer medical policies for ART are specific about what qualifies — a submission that lists only a diagnosis code and a CPT code, without the underlying workup, forces the reviewer to deny for insufficient documentation. Building a standardized clinical submission template that anticipates the reviewer's checklist eliminates most first-pass denials.

• Duration of infertility documented with a specific start date — most commercial policies require 12 months of unprotected intercourse for patients under 35 or 6 months for patients 35 and older, and the file must reflect that timeline explicitly.
• Complete female workup on file: ovulation assessment (mid-luteal progesterone or ovulation-tracking log), ovarian reserve testing (AMH, day-3 FSH, antral follicle count), tubal patency evaluation (HSG or laparoscopic operative note), and uterine cavity assessment (SIS, hysteroscopy, or 3D ultrasound).
• Complete male workup on file: at least one semen analysis performed within the past 12 months documented against WHO 2010 or 2021 reference ranges, with a repeat analysis when the first is abnormal.
• Etiologic diagnosis documented — N97.0 anovulation, N97.1 tubal, N97.2 uterine, N97.8 other female-factor, or N46.x male-factor — rather than the unspecified N97.9 or a Z31.83 encounter code as the primary diagnosis on the auth submission.
• Prior treatment history when the payer requires step therapy: documented ovulation-induction or IUI cycles with response and outcomes, or the specific clinical reason step therapy was bypassed (severe male factor per WHO cutoffs, bilateral tubal occlusion, advanced maternal age with diminished ovarian reserve, or a genetic indication for PGT).
• Cycle-specific protocol summary at the time of the auth: stimulation type (antagonist, agonist, mini-stim), medication plan, anticipated retrieval window, planned lab work (ICSI, PGT-A, PGT-M, PGT-SR), and planned transfer type (fresh vs. FET, single vs. double).
• Provider signature and NPI on the clinical summary — some payers now reject a submission that carries only a coder's or biller's signature on the clinical narrative, treating it as an incomplete medical-necessity attestation.

Tracking Active Authorizations

• Log every authorization with: payer name, auth number, authorized CPT codes, diagnosis codes, date range, and expiration date.
• Flag authorizations expiring within 30 days and proactively request extension if the cycle is still active.
• Document the authorization number on every claim line that requires one — missing auth numbers are one of the most common mechanical denial causes.
• Build a cancelled-cycle protocol: when a cycle is cancelled, note whether any authorized services were rendered and whether a new auth will be needed for the restart.

Reading Prior Authorization Denials by CARC Code

Every auth-related denial reaches the practice as a CARC/RARC combination on the EOB. Reading the codes correctly determines whether the recovery path is a corrected claim, a retro-auth request, a full appeal with clinical evidence, or a patient-financial-responsibility conversion. Misreading a CO-197 as a CO-96 sends a valid case down the wrong path and burns the payer-specific filing clock.

• CO-197 (precertification/authorization absent) — the payer did require an auth and the claim submitted without one. Recovery path: file a retro-auth request within the payer-specific window (typically 30 to 90 days from the date of service; some payers restrict retro-auth to circumstances outside the practice's control such as emergent care), then resubmit with the auth number attached. Do not appeal a CO-197 without first attempting the retro-auth — appeals of missing auths without a retro-auth attempt are routinely upheld.
• CO-198 (precertification/authorization exceeded) — the auth existed but did not cover the specific service, quantity, or date. Recovery path: identify whether the auth mismatch is CPT-level (a code was rendered that was not on the auth), quantity-level (more units billed than authorized), or date-level (service outside the auth window), then request an amended auth or file an appeal with the clinical justification for the specific mismatch.
• CO-15 (authorization number missing, invalid, or does not apply to the billed services) — the auth number is on the claim but does not match the payer's system record. Recovery path: verify the auth number against the payer's portal or the original auth letter, correct any transcription errors, and refile as a corrected claim rather than an appeal.
• CO-96 (non-covered charge — benefit exclusion) — a coverage decision rather than an authorization gap. Do not confuse with CO-197. Recovery path: route to patient financial responsibility under the plan's exclusion language, or appeal only if the exclusion is being applied to a service that should be covered under the plan's SPD or state mandate — that is a coverage-tier appeal, not an auth appeal.
• N130 (consult plan benefit documents/guidelines for information about restrictions for this service) — often paired with CO-96 or CO-197. The N-code signals that the reviewer wants the appeal to cite the specific plan-language section that supports coverage. Recovery path: obtain the SPD or COC document, quote the relevant section, and file the appeal against the plan language rather than against the general medical policy.
• PR-108 (rent/purchase guidelines were not met) — appears occasionally on IVF medication authorizations that route through a specialty pharmacy on a rental-style benefit accumulator. Recovery path: coordinate with the specialty pharmacy to confirm the auth was placed under the correct dispensing model before rebilling.
• CO-11 with an auth pattern (diagnosis inconsistent with procedure) — the auth was issued against a diagnosis that does not match the claim submission. Recovery path: reconcile the auth diagnosis with the claim diagnosis, and file a corrected claim if the claim diagnosis is the correct one, or request an amended auth if the auth was issued against an inaccurate diagnosis captured at intake.

When Authorization Is Denied

If a prior authorization request is denied, obtain the denial in writing, identify the specific reason, and appeal within the payer's stated timeframe. For clinical medical necessity denials, a peer-to-peer review between your physician and the payer's medical director is often the most effective path. Do not begin the cycle on a denied authorization expecting to retroactively resolve it — this almost never results in reimbursement and shifts the financial risk entirely to the patient or the practice.

Preparing for a Peer-to-Peer Review

Peer-to-peer reviews are the highest-leverage step in the auth-denial recovery workflow and one of the most under-prepared. The physician on the practice side has typically five to fifteen minutes with a payer medical director whose training may not be in reproductive endocrinology — the call succeeds when the physician arrives with the specific clinical facts the reviewer needs to hear framed against the payer's own medical policy language.

• Confirm the review is scheduled with a payer physician whose credentials cover the service under review. If the assigned reviewer is not board-certified in reproductive endocrinology, obstetrics-gynecology, or medical genetics, request a specialty-matched reviewer before the call — most payers accommodate this on request and the outcome data supports it.
• Read the payer's current medical policy for the denied CPT before the call. Every major commercial carrier publishes an ART or infertility medical policy that lists the specific criteria for approval. Frame the clinical case against the policy language, not against clinical consensus generally.
• Bring the full clinical file: duration of infertility with dates, complete female and male workup with lab values and imaging findings, prior treatment history with outcomes, and the etiologic diagnosis with supporting documentation.
• For PGT-M or PGT-SR reviews, include the referring geneticist letter, the specific genetic diagnosis with ICD-10 code, the family history documentation, and the couple's reproductive plan. PGT-M is often denied at first pass because the general medical-director reviewer does not have the genetics context to affirm medical necessity without a genetics referral letter.
• For patients over 40 or with diminished ovarian reserve, cite the specific ASRM committee opinion or practice guideline that supports the requested treatment. The 2024 ASRM guidance on treatment of women 40 and older, and the ASRM committee opinion on diminished ovarian reserve, are the two most commonly referenced authorities on age-related denials.
• Document the peer-to-peer outcome the same day — the reviewer's name, credentials, the specific reason for the decision, and any next-step guidance. A verbal approval that is not documented becomes a written denial when the auth letter arrives.
• If the peer-to-peer is upheld, escalate to a second-level appeal with a specialty-matched external review request. External reviews under state insurance law or ERISA are binding on the payer and reverse approximately half of upheld first-level ART denials when the clinical file is complete.